Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYCR1 | P32322 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA5A | P35218 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | MMP9 | P14780 | 2/20 | 0.31 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
| ▸ | OGG1 | O15527 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30434781 | 0.82 | PYCR1 (0.36) | PYCR1HTTALDH1A1TSHRCA1 | |
| SCHEMBL13246739 | 0.81 | TACR1 (0.41) | HTTATMALDH1A1TSHR | |
| SCHEMBL30434709 | 0.79 | HTT (0.46) | PYCR1HTTATMALDH1A1TSHR | |
| SCHEMBL15242493 | 0.77 | MAPT (0.46) | PYCR1HTTATMALDH1A1TSHR | |
| SCHEMBL838589 | 0.77 | ATM (0.33) | HTTATMALDH1A1TSHRMAPT | |
| SCHEMBL830941 | 0.77 | KIF11 (0.46) | HTTATMALDH1A1TSHRMAPT | |
| SCHEMBL30462529 | 0.75 | ALOX15 (0.40) | ALDH1A1TSHRCA1CA2CA5A | |
| SCHEMBL10160572 | 0.75 | CA1 (0.36) | ALDH1A1MAPTCA1CA2CA5A | |
| SCHEMBL830832 | 0.74 | CYP2C19 (0.42) | HTTALDH1A1MAPTCA1CA2 | |
| Hydrochloric Acid SCHEMBL25330775 | 0.74 | ALOX15 (0.39) | ALDH1A1TSHRCA1CA2CA5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143451-B2 | Reacting a ketone with an allyl boron compound anc ammonia or ammonium salt; synthons | KANATA CHEMICAL TECHNOLOGIES INC. (CA) | 2012-03-27 | — | — | US | disclosed |
| US-8143451-B2 | Reacting a ketone with an allyl boron compound anc ammonia or ammonium salt; synthons | KANATA CHEMICAL TECHNOLOGIES INC. (CA) | 2012-03-27 | — | — | US | disclosed |
| US-8143451-B2 | Reacting a ketone with an allyl boron compound anc ammonia or ammonium salt; synthons | KANATA CHEMICAL TECHNOLOGIES INC. (CA) | 2012-03-27 | — | — | US | disclosed |
| US-20080139847-A1 | METHODS OF PREPARING TERTIARY CARBINAMINE COMPOUNDS | KANATA CHEMICAL TECHNOLOGIES INC. (CA) | 2008-06-12 | — | — | US | disclosed |
| US-20080139847-A1 | METHODS OF PREPARING TERTIARY CARBINAMINE COMPOUNDS | KANATA CHEMICAL TECHNOLOGIES INC. (CA) | 2008-06-12 | — | — | US | disclosed |
| US-20080139847-A1 | METHODS OF PREPARING TERTIARY CARBINAMINE COMPOUNDS | KANATA CHEMICAL TECHNOLOGIES INC. (CA) | 2008-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139847-A1 | METHODS OF PREPARING TERTIARY CARBINAMINE COMPOUNDS | INMT, CROCC, GNMT | PYCR1 889/4885HTT 1319/4885ATM 2848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.